HealthTree

Showing 72 trials matching your filters.

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

DRUG: AVM0703

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin L...

This phase I/II trial finds out the best dose, possible benefits and/or side effects of ALX148 in combination with rituximab and lenalidomide in treating patients with indolent and aggressive B-cell non-Hodgkin lymphoma. Immunotherapy with ALX148, ma...

DRUG: CD47 Antagonist ALX148

DRUG: Lenalidomide

BIOLOGICAL: Rituximab

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previ...

BIOLOGICAL: Obinutuzumab

BIOLOGICAL: Glofitamab

DRUG: Pirtobrutinib

PROCEDURE: Tumor Imaging

PROCEDURE: Biospecimen Collection

DEVICE: ClonoSeq Assay

PROCEDURE: Bone Marrow Biopsy

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).

DRUG: Venetoclax

DRUG: Lenalidomide

DRUG: Rituximab

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MC...

To learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL.

DRUG: Rituximab

DRUG: Pirtobrutinib

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibito...

DRUG: LP-168

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell N...

This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more abou...

DRUG: Odronextamab

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Agg...

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), f...

BIOLOGICAL: Zilovertamab vedotin

DRUG: Nemtabrutinib

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (C...

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for C...

DRUG: Zanubrutinib

DRUG: Obinutuzumab

DRUG: Venetoclax

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblas...

This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

DRUG: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma

DRUG: Glofitamab

DRUG: Obinutuzumab

DRUG: Lenalidomide

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults Wi...

This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), ...

BIOLOGICAL: NKX019

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies o...

This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combi...

DRUG: voruciclib monotherapy

DRUG: voruciclib and venetoclax

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Othe...

This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabr...

DRUG: Acalabrutinib

BIOLOGICAL: Obinutuzumab

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lympho...

This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maxim...

DRUG: Selinexor

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the stud...

DRUG: Zanubrutinib

DRUG: Tafasitamab

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine a...

This phase I trial tests safety, side effects and best dose of B-cell activating factor receptor (BAFFR)-based chimeric antigen receptor T-cells, with fludarabine and cyclophosphamide lymphodepletion, for the treatment of patients with B-cell hematol...

BIOLOGICAL: Autologous BAFFR-targeting CAR T Cells

DRUG: Bendamustine

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Leukapheresis

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291...

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in...

DRUG: ABBV-291

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell T...

This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the gro...

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Cyclophosphamide

BIOLOGICAL: Cytokine-treated Veto Cells

DRUG: Fludarabine

PROCEDURE: Peripheral Blood Stem Cell Transplantation

RADIATION: Total-Body Irradiation

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall sur...

DRUG: CD22CART Infusion

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior ...

The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients...

DRUG: Zanubrutinib

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

DRUG: NX-2127

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatmen...

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cyclophosphamide

DRUG: Cyclosporine

BIOLOGICAL: Filgrastim

DRUG: Fludarabine

DRUG: Mycophenolate Mofetil

DRUG: Mycophenolate Sodium

RADIATION: Total-Body Irradiation

DRUG: Treosulfan

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Ref...

The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).

DRUG: ATA3219

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Thera...

To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.

DRUG: Acalabrutinib

DRUG: Rituximab

OTHER: Brexucabtagene Autoleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

CONFIRM: Magnetic Resonance Guided Radiation Therapy

This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved ...

RADIATION: Viewray MRIdian® Linac

Study Evaluating SC291 in Subjects with R/r B-cell Malignancies (ARDENT)

SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

DRUG: SC291

IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in...

DRUG: IKS03

Auto Stem Cell Transplant for Lymphoma Patients

This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

DRUG: Etoposide

DRUG: BCNU

DRUG: AraC

DRUG: Melphalan

PROCEDURE: Peripheral blood stem cell transplantation

BIOLOGICAL: G-CSF

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Maligna...

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

BIOLOGICAL: CTX112

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin ...

Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzu...

DRUG: Polatuzumab vedotin

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Dis...

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative ...

DRUG: Fludarabine

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

DRUG: Cyclosporine A

DRUG: Mycophenylate mofetil

BIOLOGICAL: Umbilical cord blood

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Rela...

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) ma...

DRUG: Obinutuzumab

DRUG: Glofitamab

DRUG: Rituximab

DRUG: Bendamustine

DRUG: Lenalidomide

DRUG: Tocilizumab

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the ...

DRUG: AC676

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematol...

The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblasti...

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: PRGN-3007

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (M...

DRUG: Tazemetostat Pill

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly ...

This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma. Glofitamab and obinutuzumab are monoclona...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

BIOLOGICAL: Glofitamab

DRUG: Lenalidomide

BIOLOGICAL: Obinutuzumab

PROCEDURE: Positron Emission Tomography

DRUG: Venetoclax

Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lym...

The proposed study is an open-label, single arm phase II study of venetoclax in combination with rituximab in patients over the age of 60 with previously untreated mantle cell lymphoma. The primary objective of the trial is to determine whether the c...

DRUG: Venetoclax Oral Tablet [Venclexta]

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients Wit...

The purpose of this study is to determine the most appropriate dose for the combination of ibrutinib and pembrolizumab and to see if the combination is active for the disease. The study will monitor for any side effects and if the combination of ibru...

DRUG: Ibrutinib

DRUG: Pembrolizumab

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs:...

DRUG: CD79b-19 CAR T cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

Study of SGR-1505 in Mature B-Cell Neoplasms

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

DRUG: SGR-1505

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refracto...

This phase II trial investigates the side effects of CD19 chimeric antigen receptor (CAR) T cells and acalabrutinib, and to see how well they work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to tre...

DRUG: Acalabrutinib

BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Pa...

This phase II trial studies how well ultra low dose radiation works before or after chemotherapy-free targeted therapy in treating patients with mantle cell lymphoma that has come back or does not respond to treatment. Radiation therapy uses high ene...

DRUG: Low Dose Radiation Therapy

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells with Chimeric...

The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate fea...

BIOLOGICAL: autologous hematopoietic stem cells added to planned CAR T

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel ...

DRUG: Pirtobrutinib

DRUG: Brexucabtagene Autoleucel

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being do...

RADIATION: Adaptive Bridging Radiation Therapy (ABRT)

Avo in R/R and Previously Untreated MCL

This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in th...

DRUG: Acalabrutinib

DRUG: Venetoclax

DRUG: Obinutuzumab

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

This phase II trial tests whether loncastuximab tesirine works to shrink tumors in patients with B-cell malignancies that have come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, called...

BIOLOGICAL: Loncastuximab Tesirine

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

DRUG: BGB-16673

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

DRUG: Docirbrutinib

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients...

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously ...

DRUG: Zanubrutinib

BIOLOGICAL: Rituximab

OTHER: Patient Observation

PROCEDURE: Bone Marrow Biopsy

OTHER: Fludeoxyglucose F-18

PROCEDURE: Positron Emission Tomography

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Esophagogastroduodenoscopy

PROCEDURE: Colonoscopy

PROCEDURE: Biospecimen Collection

OTHER: Questionnaire Administration

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancie...

DRUG: L-Bcl-2 antisense oligonucleotide

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

BIOLOGICAL: BAFFR-CAR T cells

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

DRUG: NX-5948

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs f...

This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the k...

DRUG: CAR.k.28

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: Bendamustine

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Follow...

This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following a stem cell transplant in treating patie...

BIOLOGICAL: Anti-CD19-CAR CMV-specific T-lymphocytes

PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Myeloablative Conditioning

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants...

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate t...

DRUG: PRT2527

DRUG: Zanubrutinib

DRUG: Venetoclax

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lym...

This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that has not responded to previous treatment (refractory)...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Lenalidomide

PROCEDURE: Lumbar Puncture

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Tafasitamab

DRUG: Venetoclax

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through th...

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult partici...

DRUG: ABBV-101

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Pa...

To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).

DRUG: Pirtobrutinib

DRUG: Venetoclax

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients with Recurrent or Refractory B-Ce...

This phase I trial studies the side effects and best dose of CD19/CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see how effective they are in treating patients with non-Hodgkin's B-cell lymphoma or chronic...

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

BIOLOGICAL: Tocilizumab

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ H...

This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.

DRUG: SYNCAR-001

DRUG: STK-009

DRUG: Cyclophosphamide

DRUG: Fludarabine

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Pat...

This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line therapy work in treating transplant-eligible pati...

DRUG: Acalabrutinib

DRUG: Bortezomib

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Doxorubicin Hydrochloride

DRUG: Prednisone

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cem...

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy ...

DRUG: ONM-501

DRUG: Cemiplimab

Study Evaluating SC262 in Subjects with R/r Non-Hodgkin's Lymphoma (VIVID)

SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

DRUG: SC262

SynKIR-310 for Relapsed/Refractory B-NHL

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

BIOLOGICAL: SynKIR-310

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by...

BIOLOGICAL: HSCT with TBI Regimen

BIOLOGICAL: HSCT with Non-TBI Regimen

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feas...

BIOLOGICAL: 8/12-Day Production of Car-T Cells

BIOLOGICAL: 8/12-Day Production of Cryopreserved Car-T Cells

BIOLOGICAL: 12-Day Production of Car-T Cells

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab i...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic ...

DRUG: Epcoritamab

DRUG: Lenalidomide

DRUG: Ibrutinib

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride [HCl]

DRUG: Prednisone

DRUG: Polatuzumab Vedotin

DRUG: Venetoclax

DRUG: CC-99282

DRUG: Pirtobrutinib

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymp...

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19)

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: anti-CD19 CAR-T cells

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell ...

This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab and how well they work together for treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not re...

DRUG: Acalabrutinib

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

BIOLOGICAL: Glofitamab

PROCEDURE: Multigated Acquisition Scan

BIOLOGICAL: Obinutuzumab

PROCEDURE: Positron Emission Tomography

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refra...

This phase I trial tests the safety, side effects, and best dose of genetically engineered cells called EGFRt/19-28z/IL-12 CAR T cells, and to see how they work in treating patients with hematologic malignancies that makes a protein called CD19 (CD19...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

BIOLOGICAL: EGFRt/19-28z/IL-12 CAR T-lymphocytes

DRUG: Fludarabine Phosphate

PROCEDURE: Leukapheresis

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

Need Help?

Legal Info

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

Get the latest thought leadership on your T-Cell Prolymphocytic Leukemia delivered straight to your inbox

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info